Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen

Kathryn J. Ruddy, Stephen D. Desantis, William Barry, Hao Guo, Caroline C. Block, Virginia Borges, Eric P. Winer, Ann H. Partridge

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Introduction In premenopausal women with breast cancer, standard adjuvant endocrine therapy has been 5 years of tamoxifen. This study sought to investigate the safety and feasibility of treating patients who remain premenopausal after adjuvant tamoxifen with gonadotropin-releasing hormone agonist (GnRH-a) concurrent with an aromatase inhibitor, mimicking the strategy that has proven effective in postmenopausal patients. Patients and Methods This phase II single-arm clinical trial aimed to enroll 50 premenopausal women who had completed > 4.5 years of adjuvant tamoxifen for a 2-year course of leuprolide (7.5 mg intramuscularly monthly or 22.5 mg intramuscularly every 3 months) and letrozole (2.5 mg orally daily). Zoledronic acid (4 mg intravenously every 6 months) was offered optionally to help prevent bone loss. Results Despite aggressive recruitment strategies at the 3 participating sites (including Dana-Farber Cancer Institute), poor accrual over 3.5 years ultimately led to early study closure after only 16 patients began therapy. Of the 16, 4 stopped treatment before 1 year, owing to toxicity; 5 completed 2 years of protocol-directed therapy; and 7 remained on treatment as of September 1, 2013, for an average of 53.5 weeks (SD, 17.2 weeks). Hot flashes, vaginal dryness, and pain were common toxicities. Conclusion Extended therapy with GnRH-a and an aromatase inhibitor (plus optional bisphosphonate) is associated with substantial side effects in premenopausal women who have already completed > 4.5 years of adjuvant tamoxifen. This study's poor accrual suggests that young women may not be highly motivated to pursue lengthier courses of endocrine therapy and that future studies of this approach may be challenging.

Original languageEnglish (US)
Pages (from-to)413-416
Number of pages4
JournalClinical breast cancer
Volume14
Issue number6
DOIs
StatePublished - Dec 1 2014

Keywords

  • Dyspareunia
  • Endocrine therapy
  • Hot flashes
  • Pain
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen'. Together they form a unique fingerprint.

Cite this